Safety profile of a taurine containing irrigation solution (AcriProTect) in pars plana vitrectomy.
OBJECTIVE
To evaluate the clinical safety of a taurine containing irrigation solution (AcriProTect) before its routine application in pars plana vitrectomy (PPV).


METHODS
Twenty-five patients who underwent PPV were included in this prospective interventional clinical study. Standard irrigation solution containing the addendum 3 mmol/L taurine was used during PPV. Postoperative follow-up visits included a standard eye examination, corneal thickness measurements, endothelial cell counts, determination of the foveal thickness by optical coherence tomography (OCT), and an electrophysiologic examination. For statistical analysis Wilcoxon test was used.


RESULTS
Significant improvement of visual acuity (VA) was observed at the 3- and 6-month controls (P = 0.024; P = 0.002 for 3 and 6 months, respectively). Endothelial cell counts and corneal thickness at 3 and 6 months were not significantly different from preoperative values (P = 0.204; P = 0.126 for endothelial cell count and P = 0.475; P = 0.095 for corneal thickness at 3 and 6 months, respectively). Both scotopic and photopic Ganzfeld electroretinography and electro-oculography did not show significant changes during the follow-up. No increase in complication rate was detected.


CONCLUSIONS
The investigation demonstrates a good biocompatibility of taurine-containing irrigation solution developed for vitrectomy in humans concomitant with habitually observed good functional outcome.
Yoeruek
Efdal
E
Department of Ophthalmology, University of Tuebingen, Germany.
Jägle
Herbert
H
Lüke
Matthias
M
Grisanti
Salvatore
S
Warga
Max
M
Krott
Ralf
R
Spitzer
Martin Stephan
MS
Tatar
Olcay
O
Bartz-Schmidt
Karl Ulrich
KU
Szurman
Peter
P
D000368:Aged; D002452:Cell Count; D003315:Cornea / Q000187:drug effects; D004585:Electrooculography / Q000187:drug effects; D004596:Electroretinography / Q000187:drug effects; D004728:Endothelium, Corneal / Q000187:drug effects; D006801:Humans; D008422:Materials Testing; D009883:Ophthalmic Solutions / Q000008:administration & dosage* / Q000009:adverse effects; D011446:Prospective Studies; D012160:Retina / Q000187:drug effects / Q000502:physiology; D012164:Retinal Diseases / Q000601:surgery; D013654:Taurine / Q000008:administration & dosage* / Q000009:adverse effects; D007507:Therapeutic Irrigation; D041623:Tomography, Optical Coherence; D014792:Visual Acuity / Q000187:drug effects; D014821:Vitrectomy
D009883:Ophthalmic Solutions; D013654:Taurine